View Item 

Show simple item record

Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records
dc.contributor.authorLentine, Krista L.
dc.contributor.authorKoraishy, Farrukh M.
dc.contributor.authorSarabu, Nagaraju
dc.contributor.authorNaik, Abhijit S.
dc.contributor.authorLam, Ngan N.
dc.contributor.authorGarg, Amit X.
dc.contributor.authorAxelrod, David
dc.contributor.authorZhang, Zidong
dc.contributor.authorHess, Gregory P.
dc.contributor.authorKasiske, Bertram L.
dc.contributor.authorSegev, Dorry L.
dc.contributor.authorHenderson, Macey L.
dc.contributor.authorMassie, Allan B.
dc.contributor.authorHolscher, Courtenay M.
dc.contributor.authorSchnitzler, Mark A.
dc.date.accessioned2019-11-12T16:22:15Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2019-11-12T16:22:15Z
dc.date.issued2019-10
dc.identifier.citationLentine, Krista L.; Koraishy, Farrukh M.; Sarabu, Nagaraju; Naik, Abhijit S.; Lam, Ngan N.; Garg, Amit X.; Axelrod, David; Zhang, Zidong; Hess, Gregory P.; Kasiske, Bertram L.; Segev, Dorry L.; Henderson, Macey L.; Massie, Allan B.; Holscher, Courtenay M.; Schnitzler, Mark A. (2019). "Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records." Clinical Transplantation 33(10): n/a-n/a.
dc.identifier.issn0902-0063
dc.identifier.issn1399-0012
dc.identifier.urihttps://hdl.handle.net/2027.42/152001
dc.description.abstractWe examined a novel linkage of national US donor registry data with records from a pharmacy claims warehouse (2007‐2016) to examine associations (adjusted hazard ratio, LCLaHRUCL) of post‐donation fills of antidiabetic medications (ADM, insulin or non‐insulin agents) with body mass index (BMI) at donation and other demographic and clinical factors. In 28 515 living kidney donors (LKDs), incidence of ADM use at 9 years rose in a graded manner with higher baseline BMI: underweight, 0.9%; normal weight, 2.1%; overweight, 3.5%; obese, 8.5%. Obesity was associated with higher risk of ADM use compared with normal BMI (aHR, 3.364.596.27). Metformin was the most commonly used ADM and was filled more often by obese than by normal weight donors (9‐year incidence, 6.87% vs 1.85%, aHR, 3.555.007.04). Insulin use was uncommon and did not differ significantly by BMI. Among a subgroup with BMI data at the 1‐year post‐donation anniversary (n = 19 528), compared with stable BMI, BMI increase >0.5 kg/m2 by year 1 was associated with increased risk of subsequent ADM use (aHR, 1.031.482.14, P = .04). While this study did not assess the impact of donation on the development of obesity, these data support that among LKD, obesity is a strong correlate of ADM use.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherregistries
dc.subject.otherantidiabetic medications
dc.subject.otherhealth outcome
dc.subject.otherliving donation
dc.subject.otherpharmacy claims
dc.subject.otherdiabetes mellitus
dc.titleAssociations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152001/1/ctr13696_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152001/2/ctr13696.pdf
dc.identifier.doi10.1111/ctr.13696
dc.identifier.sourceClinical Transplantation
dc.identifier.citedreferenceLentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med. 2010; 363 ( 8 ): 724 ‐ 732.
dc.identifier.citedreferenceOPTN (Organ Procurement and Transplantation Network)/UNOS (United Network for Organ Sharing). OPTN Policies, Policy 14: Living Donation. http://optn.transplant.hrsa.gov/governance/policies/. Accessed July 7, 2019.
dc.identifier.citedreferenceField AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10‐year period. Arch Intern Med. 2001; 161 ( 13 ): 1581 ‐ 1586.
dc.identifier.citedreferenceHsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end‐stage renal disease. Ann Intern Med. 2006; 144 ( 1 ): 21 ‐ 28.
dc.identifier.citedreferenceGrams ME, Sang Y, Levey AS, et al. Kidney‐failure risk projection for the living kidney‐donor candidate. New Engl J Med. 2016; 374 ( 5 ): 411 ‐ 421.
dc.identifier.citedreferenceLocke JE, Reed RD, Massie A, et al. Obesity increases the risk of end‐stage renal disease among living kidney donors. Kidney Int. 2017; 91 ( 3 ): 699 ‐ 703.
dc.identifier.citedreferenceSerrano OK, Sengupta B, Bangdiwala A, et al. Implications of excess weight on kidney donation: long‐term consequences of donor nephrectomy in obese donors. Surgery. 2018; 164 ( 5 ): 1071 ‐ 1076.
dc.identifier.citedreferenceDelmonico F. A report of the amsterdam forum on the care of the live kidney donor: data and medical guidelines. Transplantation. 2005; 79 ( 6 Suppl ): S53 ‐ 66.
dc.identifier.citedreferenceThe British Transplant Society and The Renal Association. The United Kingdom Guidelines for Living Donor Kidney Transplantation. 4th ed., 2018.
dc.identifier.citedreferenceAbramowicz D, Cochat P, Claas FH, et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant. 2015; 30 ( 11 ): 1790 ‐ 1797.
dc.identifier.citedreferenceSpanish Society of Nephrology (S.E.N.) and Spanish Transplant Organisation (ONT). Recommendations for living‐donor kidney transplantation. Nefrologia. 2010; 30 ( Suppl 2 ): 1 ‐ 105.
dc.identifier.citedreferenceAST Live Donor Community of Practice. Live Kidney Donor Medical Toolkit for Medical Providers. The Obese Kidney Donor. https://www.myast.org/patient-information/live-donor-toolkit. Accessed July 7, 2019.
dc.identifier.citedreferencePascual J, Abramowicz D, Cochat P, et al. European renal best practice guideline on the management and evaluation of the kidney donor and recipient. Nefrologia. 2014; 34 ( 3 ): 293 ‐ 301.
dc.identifier.citedreferenceLentine KL, Schnitzler MA, Garg AX, et al. Understanding antihypertensive medication use after living kidney donation through linked national registry and pharmacy claims data. Am J Nephrol. 2014; 40 ( 2 ): 174 ‐ 183.
dc.identifier.citedreferenceLentine KL, Lam NN, Schnitzler MA, et al. Gender differences in use of prescription narcotic medications among living kidney donors. Clin Transplant. 2015; 29 ( 10 ): 927 ‐ 937.
dc.identifier.citedreferenceLentine KL, Lam NN, Schnitzler MA, et al. Predonation prescription opioid use: a novel risk factor for readmission after living kidney donation. Am J Transplant. 2017; 17 ( 3 ): 744 ‐ 753.
dc.identifier.citedreferenceLam NN, Garg AX, Segev DL, et al. Gout after living kidney donation: correlations with demographic traits and renal complications. Am J Nephrol. 2015; 41 ( 3 ): 231 ‐ 240.
dc.identifier.citedreferenceLam NN, McArthur E, Kim SJ, et al. Gout after living kidney donation: a matched cohort study. Am J Kidney Dis. 2015; 65 ( 6 ): 925 ‐ 932.
dc.identifier.citedreferenceLentine KL, Segev DL. Better understanding live donor risk through big data. Clin J Am Soc Nephrol. 2013; 8 ( 10 ): 1645 ‐ 1647.
dc.identifier.citedreferenceLentine KL, Yuan H, Tuttle‐Newhall JE, et al. Quantifying prognostic impact of prescription opioid use before kidney transplantation through linked registry and pharmaceutical claims data. Transplantation. 2015; 99 ( 1 ): 187 ‐ 196.
dc.identifier.citedreferenceAbuelmagd MM, Nagib AM, Abuelmagd MM, et al. Study of the risk factors and complications of diabetes mellitus after live kidney donation. Transplant Proc. 2015; 47 ( 4 ): 1152 ‐ 1157.
dc.identifier.citedreferenceCenter For Disease Control. Prevalence of Obesity Among Adults and Youth: United States, 2015–2016. 2017; 2018 ( December 18 ) https://www.cdc.gov/nchs/data/databriefs/db288.pdf. Accessed July 7, 2019.
dc.identifier.citedreferenceIsbel N. The CARI guidelines. Donors at risk: obesity. Nephrology (Carlton). 2010; 15 ( Suppl 1 ): S121 ‐ 132.
dc.identifier.citedreferenceIbrahim HN, Kukla A, Cordner G, Bailey R, Gillingham K, Matas AJ. Diabetes after kidney donation. Am J Transplant. 2010; 10 ( 2 ): 331 ‐ 337.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Diabetes Report Card 2017. https://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2017-508.pdf. Accessed July 7, 2019.
dc.identifier.citedreferenceFazeli Farsani S, Souverein PC, Overbeek JA, et al. Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. Br J Clin Pharmacol. 2015; 80 ( 2 ): 294 ‐ 303.
dc.identifier.citedreferenceTaler SJ, Messersmith EE, Leichtman AB, et al. Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades. Am J Transplant. 2013; 13 ( 2 ): 390 ‐ 398.
dc.identifier.citedreferenceAmerican Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35 ( Suppl 1 ): S64 ‐ 71.
dc.identifier.citedreferenceInzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient‐centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38 ( 1 ): 140 ‐ 149.
dc.identifier.citedreferenceBerkowitz SA, Krumme AA, Avorn J, et al. Initial choice of oral glucose‐lowering medication for diabetes mellitus: a patient‐centered comparative effectiveness study. JAMA Intern Med. 2014; 174 ( 12 ): 1955 ‐ 1962.
dc.identifier.citedreferenceDiabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012; 35 ( 4 ): 731 ‐ 737.
dc.identifier.citedreferencePadwal RS. Obesity, diabetes, and the metabolic syndrome: the global scourge. Can J Cardiol. 2014; 30 ( 5 ): 467 ‐ 472.
dc.identifier.citedreferenceColditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995; 122 ( 7 ): 481 ‐ 486.
dc.identifier.citedreferenceIssa N, Askandarani S, Gillingham K, et al. Fate of living kidney donors who lost weight to become donors. (Abstract # A331). Transplantation. 2014; 98 ( Supplement 1 ): 494.
dc.identifier.citedreferenceIssa N, Sánchez OA, Kukla A, et al. Weight gain after kidney donation: Association with increased risks of type 2 diabetes and hypertension. Clin Transplant. 2018; 32 ( 9 ): e13360.
dc.identifier.citedreferenceLentine KL, Segev DL. Understanding and communicating medical risks for living kidney donors: a matter of perspective. J Am Soc Nephrol. 2017; 28 ( 1 ): 12 ‐ 24.
dc.identifier.citedreferenceEthics Committee of the Transplantation Society. The consensus statement of the Amsterdam Forum on the Care of the Live Kidney Donor. Transplantation. 2004; 78 ( 4 ): 491 ‐ 492.
dc.identifier.citedreferenceNaik AS, Cibrik DM, Sakhuja A, et al. Temporal trends, center‐level variation, and the impact of prevalent state obesity rates on acceptance of obese living kidney donors. Am J Transplant. 2018; 18 ( 3 ): 642 ‐ 649.
dc.identifier.citedreferenceVest LS, Koraishy FM, Zhang Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant. 2018; 32 ( 8 ): e13302.
dc.identifier.citedreferenceLentine KL, Kasiske BL, Levey AS, et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation. 2017; 101 ( 8S Suppl 1 ): S1 ‐ S109.
dc.identifier.citedreferenceAnjum S, Muzaale AD, Massie AB, et al. Patterns of end‐stage renal disease caused by diabetes, hypertension, and glomerulonephritis in live kidney donors. Am J Transplant. 2016; 16 ( 12 ): 3540 ‐ 3547.
dc.identifier.citedreferenceIbrahim HN, Foley RN, Reule SA, et al. Renal function profile in white kidney donors: the first 4 decades. J Am Soc Nephrol. 2016; 27 ( 9 ): 2885 ‐ 2893.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ctr13696_am.pdf
Size:
277.0KB
Format:
PDF
View/Open
Name:
ctr13696.pdf
Size:
1.133MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.